Fulgent Genetics, INC 10-Q quarterly reports

Fulgent Genetics reported a 4% revenue increase for Q2 2026, driven by its anatomic pathology segment, but faced a significant gross margin decline due to system implementation issues and increased costs.

Fulgent Genetics reported a 17% increase in third-quarter revenue driven by strong growth in precision diagnostics and BioPharma services, while significantly narrowing its net loss.

Fulgent Genetics announced a 15% revenue increase for the second quarter and first half of 2025, driven by growth in precision diagnostics, anatomic pathology, and BioPharma services, despite reporting a significantly higher net loss due to an impairment charge and increased operating expenses.

Fulgent Genetics' Q1 2025 revenue increased by 14% year-over-year, driven by growth in precision diagnostics and anatomic pathology, while the company continues to invest in its therapeutic development business.

Fulgent Genetics experienced a revenue decrease in Q3 2024, primarily due to reduced COVID-19 testing revenue, while precision diagnostics showed growth.

Fulgent Genetics reported a net loss for the second quarter of 2024, while facing ongoing legal investigations and making strategic shifts in its business segments.

Fulgent Genetics' first quarter 2024 results show a slight revenue decrease year-over-year, with shifts in segment performance and increased interest income.